Abstract
Many musculoskeletal disorders (MDs) are associated with irreversible bone and cartilage damage; this is particularly true for osteoarthritis (OA). Therefore, a clinical need exists for modalities which can detect OA and other MDs at early stages. Optical coherence tomography (OCT) is an infrared-based imaging, currently FDA approved in cardiology and ophthalmology, which has a resolution greater than 10 microns and acquisition rate of 120 frames/second. It has shown feasibility for imaging early OA, identifying changes prior to cartilage thinning both in vitro and in vivo in patients and in OA animal models. In addition, OCT has shown an ability to identify early rheumatoid arthritis (RA) and guide tendon repair, but has the potential for an even greater impact. Clinical trials in OA are currently underway, as well as in several other MDs.
Highlights
Musculoskeletal diseases are one of the leading causes of disability in the United States
Many musculoskeletal disorders (MDs) are associated with irreversible bone and cartilage damage; this is true for osteoarthritis (OA). erefore, a clinical need exists for modalities which can detect OA and other MDs at early stages
Optical coherence tomography (OCT) is an infrared-based imaging, currently FDA approved in cardiology and ophthalmology, which has a resolution greater than 10 microns and acquisition rate of 120 frames/second
Summary
Musculoskeletal diseases are one of the leading causes of disability in the United States. Is paper examines the potential of the new micronscale imaging technology and optical coherence tomography (OCT), for the management of musculoskeletal disease. It focuses on the existing clinical need for a high-resolution micron-scale imaging system in the eld of orthopedics, including osteoarthritis (OA), rheumatoid arthritis (RA), and rotator cuff repair (RCR). This is far from the full extent of potential applications. Detection of disease, understanding early disease markers, and accurate assessment of tissue microstructure are necessary to increase success of treatment, reduce patient morbidity, and determine the progress of future therapeutics in hopes of improving patient outcomes
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have